Term
|
Definition
| Inhibit P2Y12 ADP platelet receptor activation |
|
|
Term
|
Definition
| Inhibit P2Y12 ADP platelet receptor activation |
|
|
Term
|
Definition
| Inhibit platelet activator TxA2 synthesis and secretion |
|
|
Term
|
Definition
| Inhibit platelet activator TxA2 synthesis and secretion |
|
|
Term
|
Definition
| increase platelet cAMP levels by acting on PLA2 |
|
|
Term
|
Definition
| Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
| Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
| Inhibit GP IIbIIIa receptors |
|
|
Term
|
Definition
| TPO agonist; is a nonpeptide mimetic; given oral |
|
|
Term
|
Definition
| TPO agonist; is a peptide mimetic; given subcutaneous |
|
|
Term
|
Definition
| inhibits Vitamin K Epoxide Reductase = VKOR |
|
|
Term
|
Definition
| positively charged molecule that helps remove free heparin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| pentasaccharide binds to antithrombin |
|
|
Term
|
Definition
| Not used analog of fondaparinux - a pentasaccharide that binds to antithrombin |
|
|
Term
|
Definition
| biotinlated idraparinux (which is a pentasaccharide that binds to antithrombin) |
|
|
Term
|
Definition
| Direct thrombin inhibitor |
|
|
Term
|
Definition
| direct thrombin inhibitor with smaller connecting chain than hirudin |
|
|
Term
|
Definition
| Direct thromin inhibitor, binds only to catalytic site |
|
|
Term
|
Definition
| oral direct thrombin inhibitor that only binds to catalytic site |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| antibody against C5, preventing terminal compliment activation |
|
|
Term
|
Definition
| first line Fe chelator, subcu injection |
|
|
Term
|
Definition
| orally active chelating agent, but not in US b/c of potential safety problems |
|
|
Term
|
Definition
|
|
Term
|
Definition
| increase amount of HbF for sickle cell disease |
|
|
Term
|
Definition
|
|
Term
|
Definition
| structral analog of thalidomide, anti angiogenic and immunomodulatory |
|
|
Term
|
Definition
|
|
Term
|
Definition
| anti-CD52 (lymphocyte marker) |
|
|
Term
|
Definition
| alkylating agent, main toxicity is hemorrhagic cystitis |
|
|
Term
|
Definition
| alkylating agent; main toxicity is CNS effects |
|
|
Term
|
Definition
| platinum; toxicities = nephrotoxicity, nausea/vomitting, neurotoxicity, ototoxicity |
|
|
Term
|
Definition
| platnium; toxicity = myelosuppression |
|
|
Term
|
Definition
| platinum; toxicity = neurotoxicity, cold intolerance |
|
|
Term
|
Definition
| anthracycline; toxicity = cardiac, myelosuppression, nausea/vomitting |
|
|
Term
|
Definition
| antibiotic; toxicity = pulmonary, NOT bone marrow, oral mucositis |
|
|
Term
| Etoposide (epipodophyllotoxins) |
|
Definition
| Topoisomerase II inhibitor (stabilizes double stranded breaks |
|
|
Term
| Irinotecan (camptothecins) |
|
Definition
| Topoisomerase I inhibitor - stabilizes single strand breaks |
|
|
Term
|
Definition
| folate analog; inhibits dihydrofolate reductase |
|
|
Term
|
Definition
| Folate supplement used to prevent toxicity from methotrexate |
|
|
Term
|
Definition
| antimetabolite; inhibits thymidylate synthetase, which converts dUMP to dTMP |
|
|
Term
|
Definition
|
|
Term
|
Definition
| cytosine analog anti-metabolite |
|
|
Term
|
Definition
| adenosine analog anti-metabolite |
|
|
Term
|
Definition
| adenosine analog anti-metabolite |
|
|
Term
|
Definition
| adenosine analog anti-metabolite |
|
|
Term
|
Definition
| guanine analog anti-metabolite |
|
|
Term
|
Definition
| bind to tubulin to stabilize the spindle |
|
|
Term
|
Definition
| vinca alkaloid; toxicity = neuropathy |
|
|
Term
|
Definition
| vinca alkaloid; toxicity = myelosuppression |
|
|
Term
|
Definition
| radioimmunotherapy that is anti-CD |
|
|
Term
|
Definition
|
|
Term
|
Definition
| all trans retinoic acid for APL |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibitor of protein elongation (CML) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| synthetic androgen w/ anabolic properties |
|
|
Term
|
Definition
| androgen recptor antagonist |
|
|
Term
|
Definition
| androgen receptor antagonists |
|
|
Term
|
Definition
| 5alpha reductase inhibitor |
|
|
Term
|
Definition
| 5alpha reductase inhibitor |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| estrogen causing vaginal cancer |
|
|
Term
|
Definition
| androgens that bind to progestin receptors |
|
|
Term
|
Definition
|
|
Term
|
Definition
| oral synthetic progestin receptor agonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| SERM blocking feedback of estrogen |
|
|
Term
|
Definition
| progestin antagonist; glucocorticoid receptor antagonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
| integrate into bone, inhibit osteoclasts |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibit thyroid peroxidase |
|
|
Term
|
Definition
| inhibits thyroid peroxidase, inhibits T4-->T3 |
|
|
Term
|
Definition
| beta adrenergic receptor blocker |
|
|
Term
|
Definition
| inhibit thyroid hormone release; antagonize TSH, inhibit thyroid peroxidase |
|
|
Term
|
Definition
|
|
Term
|
Definition
| inhibit steroid synthesis |
|
|
Term
|
Definition
| insulin given with protamine, medium duration |
|
|
Term
|
Definition
| modifications of insulin to prevent dimerization --> quick acting |
|
|
Term
|
Definition
| modification in insulin --> less dimerization --> fast acting |
|
|
Term
|
Definition
| form microprecipitates of insulin, so longer acting |
|
|
Term
|
Definition
| form precipitates of insulin, so longer lasting |
|
|
Term
|
Definition
| closes Katp channels, leading to insulin release |
|
|
Term
|
Definition
| closes Katp channels, leading to insulin release |
|
|
Term
|
Definition
| increases glucose-dependent release of insulin, increased weight loss / satiety |
|
|
Term
| dipeptidylpeptidase inhibitors |
|
Definition
| inhibits enzyme that breaks down GLP-1 |
|
|
Term
|
Definition
| increases insulin sensitivity in muscle and adipose by binding to PPARgamma |
|
|
Term
| alpha-glucosidase inhibitor |
|
Definition
| prevents breakdown of sugars, so prevents absorption |
|
|
Term
|
Definition
| affects satiety, post prandial glucose concentrations |
|
|
Term
|
Definition
| decrease glucose production by liver, increase utilization |
|
|
